👋 Hey, let’s get into it. Biology doesn't usually make national headlines unless something has gone spectacularly wrong. This week, that honor goes to Cyclospora, the parasite behind a foodborne illness outbreak spanning 31 states with more than 800 confirmed cases and counting.

Somewhere, microbiologists are excited their favorite protozoan is finally getting attention. Everyone else is probably just side-eyeing their salad.

🇩🇪 Germany Approves Drug Pricing Reform Despite Pharma Opposition
Germany officially passed sweeping healthcare reforms designed to save roughly €16.3 billion ($18.6 billion) next year, including increasing mandatory rebates on branded medicines from 7% to 15.5%. Drugmakers successfully pushed lawmakers to abandon an even tougher variable rebate proposal, but industry groups still argue the package places a substantial financial burden on innovative pharmaceutical companies. Because Germany often serves as an early launch market for new medicines, the policy changes could influence commercialization strategies across the broader European market.

💉 Sanofi's Sarclisa Becomes First Cancer Drug Delivered by On-Body Injector
Sanofi earned FDA approval for Sarclisa Escena, making it the first subcutaneous anticancer therapy that can be delivered either manually or through an on-body injector. Clinical studies showed the new formulation matched the intravenous version for efficacy and safety while dramatically shortening treatment time for multiple myeloma patients. Delivered through Enable Injections' hands-free device, the approval could reduce workload for infusion centers while giving Sanofi a stronger competitive position against Johnson & Johnson's blockbuster multiple myeloma therapy, Darzalex.

🏭 FDA Proposes Manufacturing Overhaul to Boost U.S. Drug Supply Chain
The FDA unveiled a proposal to modernize how drug manufacturing facilities register, allowing companies operating identical "hub-and-spoke" production sites to register as a single establishment rather than navigating duplicate regulatory filings. The agency also wants to close a longstanding blind spot by requiring more foreign ingredient manufacturers to register with the FDA. Officials say the changes would reduce administrative burden for domestic manufacturers while giving regulators better visibility into global supply chains and improving their ability to respond to quality or safety concerns.

🔪 GSK's Jemperli Could Help Rectal Cancer Patients Avoid Surgery
GSK plans to seek FDA approval after its PD-1 inhibitor Jemperli delivered encouraging Phase 2 results in patients with mismatch repair deficient locally advanced rectal cancer. The study showed sustained complete clinical responses that could allow some patients to avoid chemotherapy, radiation, surgery, and even permanent colostomy bags. While the eligible patient population represents only about 5% to 10% of rectal cancer cases, the results could significantly change treatment by preserving quality of life without compromising disease control.

✅ Padcev + Keytruda Expand Into Earlier Bladder Cancer Treatment
Pfizer, Astellas, and Merck secured another FDA approval as Padcev plus Keytruda became the first perioperative treatment for muscle-invasive bladder cancer regardless of whether patients qualify for cisplatin chemotherapy. Phase 3 data showed the regimen reduced the risk of death by 35% while cutting recurrence or progression by 47% compared with chemotherapy alone. More than half of treated patients had no detectable cancer at surgery, extending the combination's momentum from advanced bladder cancer into a potentially curative setting.

😊 Start therapy today, feel better tomorrow
Get matched with a licensed therapist and get flexible support by chat, phone, or video. Take control of your mental health today and save 20% on your first month.
*Offer valid for new users only, cannot be combined with insurance

💶 Apollo Invests €3B in Bayer's Contraceptive Business
Apollo will invest €3 billion ($3.4B) for a minority stake in Bayer's contraceptive unit, giving Bayer fresh capital while maintaining operational control.

🤖 Insilico Lands $177M AI Drug Discovery Partnership
China Medical System expanded its partnership with Insilico Medicine in a deal worth up to $177 million for AI-driven CNS drug discovery.

👎 AstraZeneca and Ionis Stumble in ATTR-CM
Shares tumbled after Wainua missed a pivotal Phase 3 endpoint in ATTR cardiomyopathy, while rivals BridgeBio and Alnylam surged.

🎯 GSK's ADC Delivers Phase 3 Win
Hansoh and GSK's B7-H3 antibody-drug conjugate improved overall survival in small-cell lung cancer, supporting regulatory filings in China.

💉 Dysport Wants AbbVie’s Botox Migraine Turf
Ipsen's Botox challenger, Dysport, became the first botulinum toxin to post positive Phase 3 results in both episodic and chronic migraine prevention.

🤩 Agenus Drops One Phase 3 to Chase a $7B Prize
Agenus scrapped one colorectal cancer study to focus on MSS colon cancer, targeting a potential $7 billion U.S. market.

For decades, biotech's center of gravity has revolved around Boston and South San Francisco. But a new generation of life sciences hubs is quickly earning its place on the map. Lower costs, government support, elite universities, AI talent, and modern lab space are giving ambitious cities a chance to compete for startups, investors, and global pharma. Here are five locations quietly building the next wave of biotech innovation.

🇨🇳 Beijing is leveraging enormous government investment, world-class universities, and sprawling biotech parks to become one of the world's fastest-growing life sciences ecosystems. Global pharma giants including AstraZeneca, Bayer, and Lilly continue expanding there, while hundreds of startups call its innovation districts home.

🍻 London is pairing its legendary academic institutions with renewed venture funding and a growing AI ecosystem. Investment rebounded in early 2026, new lab space continues to open across King's Cross, Canary Wharf, and White City, and optimism is returning after several difficult years for the U.K. biotech sector.

☕️ Seattle is transforming its technology pedigree into biotech momentum. Home to a deep AI talent pool, more than 31,000 life sciences workers, and companies spanning RNA editing, genomics, and vaccines, the city has become one of the fastest-growing biotech investment destinations in the U.S.

🏔️ Basel proves size isn't everything. With Roche, Novartis, Lonza, and a thriving startup community packed into a city of fewer than 200,000 people, Switzerland's life sciences capital continues attracting companies through its research institutions, cross-border talent, and expanding innovation campuses.

🌭 Chicago rounds out the list by combining major pharma anchors like AbbVie and Astellas with strong university research, rising venture investment, and rapidly expanding lab infrastructure. The Windy City is quietly becoming one of America's most complete biotech ecosystems.

The next biotech unicorn may not come from Kendall Square. It might come from somewhere most investors weren't watching five years ago.

📖 Read the full story

ARPA-H will invest up to this much over five years through its THRIVE program to accelerate personalized genetic medicines for rare diseases. The funding backs next-generation platforms capable of creating custom therapies, including work inspired by the groundbreaking one-of-one gene therapy developed for baby KJ Muldoon. Personalized medicine is rapidly shifting from scientific curiosity toward a scalable treatment model.

Here’s what biotech Redditors are talking about:

😳 When the "Unlayoffable" are Laid Off
A Reddit thread struck a nerve after one biotech veteran shared that two colleagues they considered completely "layoff-proof" were recently let go. The discussion quickly turned into a reality check: layoffs are often driven by budgets and reorganizations, not performance. Plenty of commenters said they've watched companies eliminate top performers simply because a spreadsheet said so. The consensus? Build your network, keep your résumé updated, and never assume great work alone guarantees job security.

🎉 Is the 30-Year Work Anniversary Extinct?
Another Reddit discussion questioned whether 20- and 30-year work anniversaries are becoming relics of another era. While younger professionals argued today's layoffs and restructuring make those milestones nearly impossible, others pointed out they still happen, just usually among employees who value stability over climbing the corporate ladder. The broader takeaway wasn't that long careers no longer exist, but that today's biotech professionals are far more likely to define career success by adaptability than longevity.

💉 HHS Drafts COVID Vaccine Injury Table
HHS plans to create an official list of injuries presumed to be linked to COVID-19 vaccines, the goal is to simplify future compensation claims.

🔄 McKinsey Says AI Needs an R&D Reboot
McKinsey argues AI won't transform drug discovery unless companies redesign R&D itself instead of simply layering AI onto existing workflows.

🚫 FDA Resumes Publishing Rejection Letters
After briefly pausing the initiative, the FDA released 14 additional Complete Response Letters, restoring transparency into failed drug applications.

📈 Q32 Shares Jump 60%
Q32 surged after phase 2 alopecia data suggested its drug could become a more durable alternative to JAK inhibitors.

🔬 Bayesian Health Is Putting AI on Sepsis Watch
Sepsis kills hundreds of thousands of patients each year because clinicians often detect it too late. New York startup Bayesian Health hopes AI can change that. Its newly FDA-cleared continuous sepsis monitor constantly analyzes electronic health records to detect subtle clinical changes before patients visibly deteriorate. Backed by the Cleveland Clinic, the company aims to shift hospitals from reactive treatment to continuous, proactive monitoring that could save lives while reducing costs.

🐵 July 14, 1960: Jane Goodall Changed Biology Forever
On this day in 1960, 26-year-old Jane Goodall arrived at Tanzania's Gombe Stream Reserve, few expected her observations to rewrite biology textbooks. Just months later, she documented chimpanzees modifying sticks to fish for termites, the first evidence that animals other than humans make and use tools. Her work launched the longest-running wild chimpanzee study in history and forever changed how scientists view intelligence, evolution, and what it really means to be human.

If this week's Cyclospora outbreak has you side-eyeing your salad, I'm sure the "protein-maxxing" crowd is feeling pretty validated right now. Unfortunately for them, science still says vegetables are good for you...just preferably the ones not trying to colonize your intestines.

That’s all for today. See you Thursday for the next issue. 👋

✍️ Today’s email was brought to you by Josh Martin.

If you’re enjoying BioNucleus, share it with a friend or coworker who’d get value from it. We’re a small operation, and every share makes a bigger difference than you think.

Was this email forwarded to you? Sign up here 👇

Subscribe for free

Follow us on social and stay one step ahead

BioNucleus Briefing lands in the inboxes of 1,200+ scientists, founders, investors, operators, and industry decision-makers twice a week.

If you'd like to sponsor a future issue, just hit reply and let's talk.